Argos Therapeutics Inc. (NASDAQ:ARGS) shot up 2.7% during mid-day trading on Friday . The company traded as high as $6.19 and last traded at $6.15, with a volume of 115,123 shares changing hands. The stock had previously closed at $5.99.

A number of brokerages have issued reports on ARGS. Zacks Investment Research lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Monday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Friday, June 17th. FBR & Co reaffirmed a “buy” rating on shares of Argos Therapeutics in a research note on Tuesday, June 14th. Finally, Roth Capital lifted their price objective on shares of Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 19th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $11.84.

The stock’s market cap is $159.23 million. The company has a 50-day moving average of $6.16 and a 200 day moving average of $5.38.

Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. Analysts expect that Argos Therapeutics Inc. will post ($1.74) earnings per share for the current fiscal year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.